237 related articles for article (PubMed ID: 20109141)
1. Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists.
Radek RJ; Kohlhaas KL; Rueter LE; Mohler EG
Curr Pharm Des; 2010 Jan; 16(3):309-22. PubMed ID: 20109141
[TBL] [Abstract][Full Text] [Related]
2. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.
Hauser TA; Kucinski A; Jordan KG; Gatto GJ; Wersinger SR; Hesse RA; Stachowiak EK; Stachowiak MK; Papke RL; Lippiello PM; Bencherif M
Biochem Pharmacol; 2009 Oct; 78(7):803-12. PubMed ID: 19482012
[TBL] [Abstract][Full Text] [Related]
3. Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction.
Cincotta SL; Yorek MS; Moschak TM; Lewis SR; Rodefer JS
Curr Opin Investig Drugs; 2008 Jan; 9(1):47-56. PubMed ID: 18183531
[TBL] [Abstract][Full Text] [Related]
4. Nicotinic-antipsychotic drug interactions and cognitive function.
Levin ED; Rezvani AH
EXS; 2006; 98():185-205. PubMed ID: 17019889
[TBL] [Abstract][Full Text] [Related]
5. A Novel Multisensory Integration Task Reveals Robust Deficits in Rodent Models of Schizophrenia: Converging Evidence for Remediation via Nicotinic Receptor Stimulation of Inhibitory Transmission in the Prefrontal Cortex.
Cloke JM; Nguyen R; Chung BY; Wasserman DI; De Lisio S; Kim JC; Bailey CD; Winters BD
J Neurosci; 2016 Dec; 36(50):12570-12585. PubMed ID: 27974613
[TBL] [Abstract][Full Text] [Related]
6. The role of the α7 nicotinic receptor in cognitive processing of persons with schizophrenia.
AhnAllen CG
Curr Opin Psychiatry; 2012 Mar; 25(2):103-8. PubMed ID: 22262029
[TBL] [Abstract][Full Text] [Related]
7. Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking.
Ochoa EL; Lasalde-Dominicci J
Cell Mol Neurobiol; 2007 Aug; 27(5):609-39. PubMed ID: 17554626
[TBL] [Abstract][Full Text] [Related]
8. Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia.
Boggs DL; Carlson J; Cortes-Briones J; Krystal JH; D'Souza DC
Curr Pharm Des; 2014; 20(31):5077-92. PubMed ID: 24345265
[TBL] [Abstract][Full Text] [Related]
9. Targeting α4β2 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach.
Grupe M; Grunnet M; Bastlund JF; Jensen AA
Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):187-200. PubMed ID: 25441336
[TBL] [Abstract][Full Text] [Related]
10. Advances in the In vitro and In vivo pharmacology of Alpha4beta2 nicotinic receptor positive allosteric modulators.
Wilkerson JL; Deba F; Crowley ML; Hamouda AK; McMahon LR
Neuropharmacology; 2020 May; 168():108008. PubMed ID: 32113032
[TBL] [Abstract][Full Text] [Related]
11. The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia.
Rajagopal L; Massey BW; Huang M; Oyamada Y; Meltzer HY
Curr Pharm Des; 2014; 20(31):5104-14. PubMed ID: 24345269
[TBL] [Abstract][Full Text] [Related]
12. Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology.
Thomsen MS; Hansen HH; Timmerman DB; Mikkelsen JD
Curr Pharm Des; 2010 Jan; 16(3):323-43. PubMed ID: 20109142
[TBL] [Abstract][Full Text] [Related]
13. The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents.
Boess FG; De Vry J; Erb C; Flessner T; Hendrix M; Luithle J; Methfessel C; Riedl B; Schnizler K; van der Staay FJ; van Kampen M; Wiese WB; Koenig G
J Pharmacol Exp Ther; 2007 May; 321(2):716-25. PubMed ID: 17308038
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.
Beinat C; Banister SD; Herrera M; Law V; Kassiou M
CNS Drugs; 2015 Jul; 29(7):529-42. PubMed ID: 26242477
[TBL] [Abstract][Full Text] [Related]
15. Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.
Levin ED; Rezvani AH
Biochem Pharmacol; 2007 Oct; 74(8):1182-91. PubMed ID: 17714691
[TBL] [Abstract][Full Text] [Related]
16. The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.
Rollema H; Hurst RS
Psychopharmacology (Berl); 2018 Sep; 235(9):2479-2505. PubMed ID: 29980822
[TBL] [Abstract][Full Text] [Related]
17. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia.
Zhang XY; Liu L; Liu S; Hong X; Chen DC; Xiu MH; Yang FD; Zhang Z; Zhang X; Kosten TA; Kosten TR
Am J Psychiatry; 2012 Sep; 169(9):974-81. PubMed ID: 22952075
[TBL] [Abstract][Full Text] [Related]
18. Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.
Olincy A; Stevens KE
Biochem Pharmacol; 2007 Oct; 74(8):1192-201. PubMed ID: 17714692
[TBL] [Abstract][Full Text] [Related]
19. Anabasine, a selective nicotinic acetylcholine receptor agonist, antagonizes MK-801-elicited mouse popping behavior, an animal model of schizophrenia.
Mastropaolo J; Rosse RB; Deutsch SI
Behav Brain Res; 2004 Aug; 153(2):419-22. PubMed ID: 15265637
[TBL] [Abstract][Full Text] [Related]
20. Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
Martin LF; Freedman R
Int Rev Neurobiol; 2007; 78():225-46. PubMed ID: 17349863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
